Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Lung Cancer
About this trial
This is an interventional treatment trial for Lung Cancer focused on measuring stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed stage IIIB or IV non-small cell lung cancer not amenable to combination chemotherapy, curative surgery, or radiotherapy Bidimensionally measurable disease PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life expectancy: At least 12 weeks Hematopoietic: Granulocyte count at least 2,000/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT less than 2.5 times ULN Alkaline phosphatase less than 5 times ULN (except in cases of bone or liver metastases) Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No unstable or uncontrolled cardiac disease Pulmonary: No history of recurrent aspiration pneumonitis within the past 3 months Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 9 days after study Able to swallow capsules intact No active infection within the past 2 weeks No unstable or uncontrolled medical conditions No other prior malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix No history of peripheral neuropathy with severity greater than CALGB grade 1 PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunologic therapy At least 1 week since prior hematopoietic growth factors or other blood products Chemotherapy: See Disease Characteristics No prior chemotherapy No other concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy Surgery: See Disease Characteristics At least 2 weeks since prior surgery Other: At least 4 weeks since prior investigational device or drug No other concurrent anticancer therapy No other concurrent investigational device or drug
Sites / Locations
- Arizona Clinical Research Center
- Veterans Affairs Medical Center - Tucson
- Highlands Oncology Group, P.A.
- Genesis Cancer Center
- NorthBay Healthcare System
- Wilshire Oncology Medical Center
- Cancer Care Consultants of Northern California
- Comprehensive Cancer Care Specialists of Boca Raton
- West Florida Cancer Institute - Pensacola
- University of Chicago Cancer Research Center
- South Bend Clinic and SurgiCenter
- Medical Oncology, LLC
- Office of Luis Alberto Meza
- Berkshire Physicians and Surgeons, P.C.
- Barbara Ann Karmanos Cancer Institute
- Sparrow Regional Cancer Center
- Lakeland Medical Center - St. Joseph
- Providence Hospital Cancer Center
- St. Luke's Hospital
- Washington University Barnard Cancer Center
- Mercy Oncology-Hematology Limited
- Cancer Resource Center - Lincoln
- Norris Cotton Cancer Center
- Trinitas Hospital - Jersey Street Campus
- Northern NJ Cancer Associates
- Lovelace Health Systems
- Veterans Affairs Medical Center - Buffalo
- Office of Hal Gerstein
- Saint Vincents Comprehensive Breast Center
- NYU School of Medicine's Kaplan Comprehensive Cancer Center
- Veterans Affairs Medical Center - Northport
- University of Rochester Cancer Center
- Office of Janak K. Choksi
- Raleigh Hematology/Oncology Associates - Wake Practice
- Comprehensive Cancer Center at Wake Forest University
- Ireland Cancer Center
- Hematology Oncology Consultants Inc
- HillCrest Hospital
- University of Pittsburgh Cancer Institute
- Cancer Centers of the Carolinas
- West Clinic, P.C.
- Memphis Cancer Center
- Simmons Cancer Center - Dallas
- Medical Group of Texas
- Joe Arrington Cancer Center
- MultiCare Hematolgy/Oncology Clinic
- Lakeridge Health Oshawa
- McGill University
- Veterans Affairs Medical Center - San Juan
- University of Puerto Rico School of Medicine Medical Sciences Campus